| Document Date: 2013-11-19 17:56:54
Open Document File Size: 111,21 KBShare Result on Facebook
City London / Bethlehem / / Company Saladax Biomedical Inc. / Novartis / The New England Journal / DxS Ltd / Qiagen / JDF PharmaConsulting LLC / AstraZeneca / Myriad Genetics / DATAMONITOR / / Country Guinea / United States / / Currency USD / / Event FDA Phase / Business Partnership / / Facility Tufts Center / / IndustryTerm oncology products / pharmaceutical industry / biotechnology industries / cancer therapy / Dose management / pharmaceutical/diagnostic partnerships / proper diagnostic tools / / MedicalCondition colorectal cancer / yeloid leukemia / gastrointestinal stromal tumors / non-small-cell lung cancer / hand carcinomas / neck carcinomas / cancer / tumors / disease / NSCLC / metastatic colorectal cancer / chronic myeloid leukemia / Individualized cancer / / MedicalTreatment adjuvant chemotherapy / chemotherapy / cancer therapy / / MusicAlbum July / / Organization National Institute of Health / FDA / Tufts Center for the Study of Drug Development / / Person J. Salamone / Francis Collins / Margaret Hamburg / Jack DeForrest / Edward L. Erickson / Phil Trans / / Position President / physician / President & Chief Executive Officer / Chief Scientific Officer / Governor / / Product Iressa / fluorouracil / drug / / ProvinceOrState Pennsylvania / / PublishedMedium The New England Journal of Medicine / / Technology Pharmacogenomic / diagnostic tests / biotechnology / pharmacokinetics / Drug Discovery / chemotherapy / treating cancer / Drug Development / / URL http /
SocialTag |
Therapy Dose Management During Clinical Development of Oncology Products Salvatore J. Salamone, PhD, Founder & Chief Scientific Officer; Edward L. Erickson, President & Chief Executive Officer; Saladax Biomedical Inc., B